Mometasone furoate microemulsion is a safe and effective therapy in the treatment of symptomatic erosive-ulcerative OLP.

ObjectiveTo evaluate the efficacy, tolerability and acceptability of Zelesse®, an intimate hygiene wash solution, in the relief of the symptoms and signs of non-specific vulvovaginitis in paediatric patients.MethodsThe NINESSE Study was a prospective, observational, multicentre study involving females aged 2–8 years who attended paediatric offices with symptoms suggestive of non-specific vulvovaginitis. They were administered Zelesse® as a single treatment for 15 ± 5 days. Pruritus, burning, dysuria, erythema, leucorrhoea and oedema were evaluated before and after treatment.ResultsA total of 71 paediatric patients were enrolled in the study (mean ± SD age, 4.5 ± 1.9 years). The most significant effects were observed for pruritus and burning, where 98.4% (62 of 63) and 96.9% (63 of 65) of the patients improved after treatment, respectively. Zelesse® demonstrated a beneficial effect on dysuria, erythema, leucorrhoea and oedema. The effects on the symptoms and signs were observed within the first week of treatment; although 44.9% (31 of 69) of patients experienced improvements after 2–3 days. Zelesse® was well accepted and tolerated by most patients. No serious adverse events were reported.ConclusionsZelesse® was very effective for the relief of the symptoms and signs of non-specific vulvovaginitis, in particular pruritus, burning and erythema, in females aged 2–8 years.

CONCLUSIONS: Financial expenditures for antineoplastic agents are rising due to use of new and expensive medications, which are supposed to double within coming years and are expected to decrease one third of cancer mortality. Senescent population with higner incidence of cancer disease is expected to slightly increase DID and medicine packages consumption. OBJECTIVES:Breast cancer forms in tissues of the breast, usually in ducts and lobules. It is the most common type of woman's cancer in Slovakia (age-standardized rate-48, incidence rate -2016 new cases every year, mortality rate 773 deaths annually ). The aim of this study was to provide comparable and reliable data of utilisation of stage I (invasive, up to 2 centimeters, no lymph nodes involved) and stage II (invasive, 2-5 centimeters, lymph nodes might be involved, over 5 centimeters-no lymph nodes involvement) breast cancer drugs within the period 2004-2009. METHODS: Analysed data were abstracted from Slovak Institute for Drug Control, which collects them from wholesalers. Data were studied in accordance with Daily Defined Dose (DDD, with exception of trastuzumab) and in financial units (€). RESULTS: The consumption of drugs used in stage I and II breast cancer had increasing trend in terms of financial burdens between 2004 and 2009 with anastrozole ( from 1 378 317 € to 1 888 478 €),, doxorubicine (from 776 400 € to 1 354 072 €), methotrexate ( from 138 954 € to 650 993 €) and trastuzumab (from 359 797 € to 11 703 935 €) decreasing trend with tamoxifen ( from 261 417 € to 159 064 €) nad alternating trend with cyclofosfamide ( 206 156